Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Mabruxixafor联合伊布替尼治疗华氏巨球蛋白血症：已开始Ib期临床试验

2019-12-31 Allan MedSci原创

华氏巨球蛋白血症伊布替尼Mabruxixafor
关注

X4 Pharmaceuticals是一家临床阶段的生物制药公司，致力于开发治疗罕见疾病的新型疗法，近日宣布，已启动mavorixafor（X4P-001）联合伊布替尼（Imbruvica）治疗华氏巨球蛋白血症（WM）的Ib期临床试验。

X4 Pharmaceuticals是一家临床阶段的生物制药公司，致力于开发治疗罕见疾病的新型疗法，近日宣布，已启动mavorixafor（X4P-001）联合伊布替尼（Imbruvica）治疗华氏巨球蛋白血症（WM）的Ib期临床试验。WM是一种非霍奇金淋巴瘤的罕见形式。Mavorixafor是趋化因子受体CXCR4的潜在口服型小分子拮抗剂。

哈佛医学院教授，医学博士Steven Treon博士说：“对于具有CXCR4突变的WM患者，医疗需求仍未得到满足。开发治疗性CXCR4拮抗剂（如mavorixafor）代表了对该疾病进行靶向治疗的重要进展” 。


原始出处：

https://www.firstwordpharma.com/node/1690365?tsid=4

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (45)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-08-13 villahu

    #Mabruxixafor#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-11-28 bioon3

    #Ib期#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-01-10 xzw113

    #球蛋白#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-08-27 snf701207

    #mAb#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-22 sghpv

    学习了，砥砺前行！

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-21 sghpv

    学习了，砥砺前行！

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-20 sghpv

    学习了，砥砺前行！

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-14 sghpv

    学习了，砥砺前行！

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-12 sghpv

    学习了，砥砺前行！

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2042077, encodeId=0e7c20420e71f, content=<a href='/topic/show?id=c96f11206ff' target=_blank style='color:#2F92EE;'>#Mabruxixafor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11206, encryptionId=c96f11206ff, topicName=Mabruxixafor)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf1b289, createdName=villahu, createdTime=Thu Aug 13 23:54:00 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940342, encodeId=232a1940342fe, content=<a href='/topic/show?id=c0e7932e64' target=_blank style='color:#2F92EE;'>#Ib期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9327, encryptionId=c0e7932e64, topicName=Ib期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Sat Nov 28 16:54:00 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035209, encodeId=3d2c203520937, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Jan 10 00:54:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912279, encodeId=60e919122e960, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Aug 27 16:54:00 CST 2020, time=2020-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379536, encodeId=13323e9536bc, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Sat Feb 22 19:30:30 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379486, encodeId=ee1a3e9486e4, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 21 14:52:16 CST 2020, time=2020-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379436, encodeId=a67a3e943666, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Thu Feb 20 08:54:08 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379211, encodeId=f7ed3e92111f, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Fri Feb 14 00:24:45 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379152, encodeId=05243e9152ff, content=学习了，砥砺前行！, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/30/ec1b6ebaf9cd7a2d3e2801f8a3ee80ce.jpg, createdBy=797e5256446, createdName=sghpv, createdTime=Wed Feb 12 15:31:55 CST 2020, time=2020-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378824, encodeId=47e43e882457, content=期待下一步研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8d1b5190105, createdName=147159abm36暂无昵称, createdTime=Sun Feb 02 20:18:14 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-02 147159abm36暂无昵称

    期待下一步研究

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

“淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识(2016年版)”解读

2016年中国抗癌协会血液肿瘤委员会、中华医学会血液学分会白血病淋巴瘤学组和中国抗淋巴瘤联盟组织国内专家共同制定了“淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识2016年版”。限于篇幅，本共识仅仅给出了涉及淋巴浆细胞淋巴瘤/WM诊断和治疗最为重要的信息。另外,由于血液科医师在临床上更多见的是WM,而非淋巴浆细胞淋巴瘤。因此,在此结合共识内容对WM进行进一步介绍,以提高大家对此类少见疾病

病例分享：淋巴浆细胞淋巴瘤/华氏巨球蛋白血症？一例分析

患者男，68岁，主因：左侧胸痛5个月，呼吸困难半个月入院。

Imbruvica®（依鲁替尼）联合利美罗华®（妥昔单抗）治疗罕见华氏巨球蛋白血症III期成功

美国生物技术巨头艾伯维近日宣布，评估靶向抗癌药Imbruvica®（ibrutinib，依鲁替尼）联合瑞士制药巨头罗氏单抗类抗癌药美罗华®（Rituxan，通用名：rituximab，利妥昔单抗）治疗华氏巨球蛋白血症（WM）的一项III期临床研究iNNOVATE（PCYC-1127）达到了主要终点。iNNOVATE是一项随机、双盲、安慰剂对照研究，由艾伯维旗下公司Pharmacyclics赞助

2016淋巴浆细胞淋巴瘤/华氏巨球蛋白血症诊断与治疗中国专家共识发布

淋巴浆细胞淋巴瘤/华氏巨球蛋白血症（lymphoplasmacytic lymphoma / Waldenströmmacroglobulinemia，LPL/WM）是一种少见的惰性成熟B细胞淋巴瘤，在非霍奇金淋巴瘤中所占比例<2%。近年来国际上对LPL/WM发病机制、诊断和治疗的研究均取得较大进展，而国内对LPL/WM认识较晚，对其诊断、治疗比较混乱，为提高我国临床工作者对LPL/WM的认

2018 ESMO临床实践指南：华氏巨球蛋白血症的诊断，治疗和随访

2018年6月，欧洲肿瘤内科学会(ESMO)发布了华氏巨球蛋白血症的诊断，治疗和随访指南，华氏巨球蛋白血症是一种罕见的疾病约占非霍奇金淋巴瘤的1%-2%。本文主要针对该病的诊断，治疗和随访的相关内容提出指导建议，涉及疾病诊断，分期和风险评估，临床管理，治疗应答评估，个体化医疗，随访以及长期影响等。

BTK抑制剂ONO-4059寻求在日本的生产和销售许可，用于治疗华氏巨球蛋白血症和淋巴浆细胞性淋巴瘤

小野制药株式会社近日宣布，已经在日本提交了盐酸Tirabrutinib（ONB-4059，BTK抑制剂）的申请，用于治疗华氏巨球蛋白血症（WM）和淋巴浆细胞性淋巴瘤（LPL）患者。

Baidu
map
Baidu
map
Baidu
map